AlphAIalphai — Financial news for AI agents
insidermonkey.comAUG 213 min read$CLBT

Cellebrite (CLBT): CEO Shift and Guidance Cuts Contrast With Surging AI and FedRAMP Gains

Cellebrite (CLBT) appointed Shiven Ramji as CEO and reduced its 2026 revenue and ARR targets due to delayed government deals. Despite this, Q2 saw 21% ARR growth to $508M, 16% revenue growth to $131M, and raised adjusted EBITDA guidance. The company highlighted growth in defense, federal, and Asia Pacific regions, as well as early success with its AI platform, Genesis.

Original reporting
insidermonkey.com
Published Aug 21, 2026, 9:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 21, 2026, 10:27 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Cellebrite (CLBT): CEO Shift and Guidance Cuts Contrast With Surging AI and FedRAMP Gains — source image
Source · insidermonkey.com
Decision brief

The 30-second read

$CLBTBearishMed
01

Why it matters

The guidance cut signals short‑term earnings pressure, but the AI platform Genesis and FedRAMP contract suggest longer‑term upside.

02

Market read

The news combines leadership change with a material guidance downgrade, likely prompting traders to reassess CLBT's valuation.

03

What to watch

Currency headwinds from the shekel and interim product leadership may be temporary and not impact long‑term growth.

Relevance 7/10Novelty 6/10Timing: pre‑market today

Background

Cellebrite, a provider of digital forensics and data extraction tools, reported a CEO transition and lowered its 2026 outlook after missing key government contracts.

Company-level read

Ticker impact

$CLBTBearishMedium confidence
Context

Cellebrite announced a new CEO and cut its full-year 2026 revenue and ARR guidance after missing large government deals.

Expected impact

downward pressure, potential 5‑10% decline over the next week

Evidence & confidence

Guidance reductions and CEO turnover are bearish catalysts; however, AI product traction and FedRAMP win provide some upside offset.

Market effects

Sector

Highlights volatility in the government‑software and AI‑enabled security sector.

Regional

US federal contract delays may affect other defense‑tech firms.

Global

Shows challenges for AI‑focused firms expanding into regulated markets worldwide.

Counterpoint

What could challenge this read

AI product traction and FedRAMP win could accelerate revenue growth, making the stock undervalued after the cut.

Key entities

  • person
    Shiven Ramji

    New CEO of Cellebrite effective Aug 13, 2026.

  • person
    Tom Hogan

    Outgoing CEO of Cellebrite.

Read at source← All news

Related articles

AUG 20
$CLBTMedAI 8/10

Cellebrite (CLBT) Q2 2026 Earnings Call Transcript

Cellebrite (CLBT) announced Shiv Ramji as its new CEO, replacing Tom Hogan. The company missed Q2 revenue expectations due to delayed large transactions and lower-than-expected ARR uplift. Despite this, they raised their full-year adjusted EBITDA target. Ramji outlined plans to improve sales execution and forecasting discipline. The company sees growth in new products and federal business, with a 25% increase in Defense and Intelligence ARR.

yahoo.com3 min
AUG 16
$CLBTMedAI 8/10

Why Cellebrite DI (CLBT) Is Down 30.4% After Cutting 2026 Outlook And Announcing CEO Transition

Cellebrite DI Ltd. reported half-year 2026 results and cut its full-year revenue outlook to US$555 million to US$561 million, implying 17% to 18% growth. The company also announced a CEO transition, with Shiven Ramji succeeding Thomas E. Hogan. The guidance reduction, weaker profitability, and delayed large government contracts contributed to a sharp stock drop.

simplywall.st6 min
AUG 15
$CLBTMedAI 8/10

Cellebrite DI Ltd. Q2 2026 Earnings Call Summary

Cellebrite DI Ltd. reported Q2 2026 results below expectations, citing delayed large transactions and procurement hurdles tied to foreign entity status. Full-year ARR guidance was cut to $550m–$560m, while adjusted EBITDA was raised to $153m–$159m. Management said Insights installed base reached 65% and Genesis launched with $400k ARR.

yahoo.com6 min
AUG 14
$CLBTMed

Cellebrite (CLBT) Stock Rebounds As ARR Grows But Outlook Cools

Simply Wall St reports Cellebrite (CLBT) shares rose about 3% after results despite a prior 30% drop. Q2 revenue was US$131.1m (up from US$113.3m), while ARR was US$508m (up from US$420m). Management raised full-year adjusted EBITDA margin guidance to the high 20s but trimmed ARR outlook to US$550m to US$560m.

simplywall.st3 min
AUG 14
$CLBTMedAI 8/10

Kaplan Fox is Investigating Cellebrite DI Ltd. (NASDAQ: CLBT) for Potential Securities Law Violations

Kaplan Fox said it is investigating Cellebrite DI Ltd. (NASDAQ: CLBT) for potential securities law violations. The firm cited Cellebrite’s Aug. 13, 2026 Q2 results: ARR of $507.8 million, below prior guidance, and a full-year ARR guidance cut of about $15 million at the midpoint, plus a CEO change replacing Tom Hogan with Shiv Ramji. CLBT shares fell about 29% to $10.80.

theglobeandmail.com4 min
AUG 14
$CLBTMed

Cellebrite DI (CLBT) Names Shiven Ramji CEO As Revenue Guidance Is Cut

Cellebrite DI (NasdaqGS: CLBT) announced CEO succession, naming Shiven Ramji, President, Products and Technology, to become CEO. The company also revised its full-year revenue guidance downward versus its prior outlook and reshaped board responsibilities for the transition. The changes affect investors focused on its recurring subscription revenue model.

simplywall.st3 min